<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620359</url>
  </required_header>
  <id_info>
    <org_study_id>BC006</org_study_id>
    <nct_id>NCT01620359</nct_id>
  </id_info>
  <brief_title>Study of ExAblate Focused Ultrasound Ablation of Breast Cancer</brief_title>
  <official_title>Study of ExAblate Focused Ultrasound Ablation of Breast Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective, non-randomized, single-arm, multi site, international study is&#xD;
      to develop data to evaluate the safety and effectiveness of the ExAblate MRgFUS system in the&#xD;
      ablation of breast cancer and of MRI.&#xD;
&#xD;
      The goal of MRgFUS ablation of breast cancer is to plan and ablate the entire tumor volume in&#xD;
      a treatable and device accessible location.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this international, non-randomized, single-arm study, a total of 200 patients with a&#xD;
      positive diagnosis of invasive breast cancer with a scheduled surgical resection will be&#xD;
      enrolled into the trial. Eligible participants will be evaluated and treated with ExAblate&#xD;
      breast ablation prior to their planned definitive surgical treatment. After the 10 to 21 days&#xD;
      post ExAblate therapy, study participants will have another contrast-enhanced MR imaging&#xD;
      examination. Their planned tumor excision will then be completed no later than 14 days from&#xD;
      the contrast-enhanced, post ExAblate procedure MR imaging examination. Additionally, the end&#xD;
      points of the study will be compared against the CORE Pathology Lab results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>5 weeks post treatment</time_frame>
    <description>To evaluate the incidence and severity of the ExAblate MRgFUS device-related complications to establish the safety profile of the ExAblate ablation of breast cancer visible on contrast-enhanced MRI with 5-10 mm margins around the primary tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histopathological analyses</measure>
    <time_frame>5 weeks post treatment</time_frame>
    <description>To estimate the effectiveness of ExAblate MRgFUS to ablate 100% of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MR imaging</measure>
    <time_frame>5 weeks post treatment</time_frame>
    <description>To estimate the sensitivity of post-ablation MRI in identifying residual disease following ablation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ExAblate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate MRgFUS</intervention_name>
    <description>100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor</description>
    <arm_group_label>ExAblate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women age 18 years with invasive breast cancer&#xD;
&#xD;
          2. Patient with contrast-enhanced MR imaging confirming a single focal breast lesion less&#xD;
             than 2 cm in diameter&#xD;
&#xD;
          3. Lesion clearly seen on contrast-enhanced MR and in a treatable location&#xD;
&#xD;
          4. Patient who is willing to undergo and be scheduled for sentinel lymph node biopsy&#xD;
&#xD;
          5. Patient scheduled and consented to surgical (lumpectomy or mastectomy) resection of&#xD;
             the breast cancer&#xD;
&#xD;
          6. Patient with clinical Stage I disease: T1 M0 N0&#xD;
&#xD;
          7. Patient who signs an informed consent form for screening, SLNB, ablation, and&#xD;
             follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Invasive lobular carcinoma;&#xD;
&#xD;
          2. DCIS without invasive components on core biopsy;&#xD;
&#xD;
          3. Tamoxifen, Aromatase Inhibitors, and Neoadjuvant chemotherapy within 30 days prior to&#xD;
             ExAblate.&#xD;
&#xD;
          4. Prior XRT or ablative therapy to the target breast;&#xD;
&#xD;
          5. Patients currently receiving anticoagulation therapy within the previous 14 days;&#xD;
&#xD;
          6. Lesions difficult to target (&lt;1 cm from skin, nipple or the rib cage), as visualized&#xD;
             on pre-therapy MRI;&#xD;
&#xD;
          7. Microcalcifications as the only sign of breast cancer on imaging studies;&#xD;
&#xD;
          8. Extensive intraductal components (EIC) on core biopsy.&#xD;
&#xD;
          9. Patients with breast implants;&#xD;
&#xD;
         10. Patients with prior surgical clips or other markers at the site of the breast tumor;&#xD;
&#xD;
         11. Patients with severe cerebrovascular disease (multiple CVA or CVA within 6 months);&#xD;
&#xD;
         12. hemolytic anemia (hematocrit &lt; 30);&#xD;
&#xD;
         13. Pregnant or lactating, post-partum women;&#xD;
&#xD;
         14. Patient overall health status of ASA &gt;2&#xD;
&#xD;
         15. Patient with active and ongoing infection at any body site;&#xD;
&#xD;
         16. Poor blood glucose control.&#xD;
&#xD;
         17. Severe hypertension&#xD;
&#xD;
         18. Patients with unstable cardiac status&#xD;
&#xD;
         19. Contraindication to MR or ExAblate ablation therapy&#xD;
&#xD;
         20. Patient with history of deep vein thrombosis&#xD;
&#xD;
         21. With history of pulmonary embolism;&#xD;
&#xD;
         22. Patient with sleep apnea;&#xD;
&#xD;
         23. Patient with airway problems;&#xD;
&#xD;
         24. Patient with severe claustrophobia;&#xD;
&#xD;
         25. Patient with non-MRI compatible implanted metal devices;&#xD;
&#xD;
         26. Patient with difficulty lying prone and still for up to 3 hours (180 minutes) in the&#xD;
             MR unit;&#xD;
&#xD;
         27. Patient who cannot fit comfortably in the magnet or patients &gt;250 lbs;&#xD;
&#xD;
         28. Patient with prior reaction to contrast agent;&#xD;
&#xD;
         29. Patient with history of grand mal seizures;&#xD;
&#xD;
         30. Patient with severely impaired renal function with estimated glomerular filtration&#xD;
             rate &lt;30 mL/min/1.73m2 and/or who is on dialysis;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Kolberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FUS BOTTROP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Bottrop</city>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://WWW.INSIGHTEC.COM</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast tumor</keyword>
  <keyword>stage 1 disease</keyword>
  <keyword>T1 M0 N0</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

